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BiosynthesisAbstract Secnidazole (a,2-Dimethyl-5-nitro-1H-imidazole-1-ethanol) is a highly effective drug
against a variety of G+/G bacteria but with signiﬁcant side effects because it is being used in very
high concentration. In this study, gold nanoparticles (GNPS) were selected as a vehicle to deliver
secnidazole drug at the speciﬁc site with more accuracy which made the drug highly effective at sub-
stantially low concentrations. The as-synthesized GNPs were capped with Human Serum Albumin
(HSA) and subsequently bioconjugated with secnidazole because HSA provides the stability and
improves the solubility of the bioconjugated drug, secnidazole. The quantiﬁcation of covalently bio-
conjugated secnidazole with HSA encapsulated on enzymatically synthesized GNPs was done with
RP-HPLC having SPD-20 A UV/VIS detector by using the C-18 column. The bioconjugation of
GNPs with secnidazole was conﬁrmed by Transmission Electron Microscopy (TEM) and Dynamic
Light Scattering (DLS). The bioconjugated GNPs were characterized by UV–VIS spectroscopy,
TEM, Scanning Electron Microscopy (SEM) and DLS. Zeta potential conﬁrmed the stability
and uniform distribution of particles in the emulsion of GNPs. The separation of bioconjugated
GNPs, unused GNPs and unused drug was done by gel ﬁltration chromatography. The minimal
inhibitory concentration of secnidazole-conjugated gold nanoparticles (Au-HSA-Snd) against
Klebsiella pneumonia (NCIM No. 2957) and Bacillus cereus (NCIM No. 2156) got improved by
12.2 times and 14.11 times, respectively, in comparison to pure secnidazole. Precisely, the MIC
of Au-HSA-Snd against K. pneumonia (NCIM No. 2957) and B. cereus (NCIM No. 2156) were
Improved efﬁciency and stability of secnidazole – An ideal delivery system 43found to be 0.35 and 0.43 lg/ml, respectively whereas MIC of the pure secnidazole drug against the
same bacteria were found to be 4.3 and 6.07 lg/ml, respectively.
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Inorganic nanoparticles have emerged as one of the best drug
delivery systems among the existing engineered nanomaterials
(Mieszawska et al., 2014; Heo et al., 2012; Wu et al., 2005;
Salem et al., 2003). They have wide bioavailability, low toxic-
ity, rich functionality, and good biocompatibility, potential
capability of targeted and controlled delivery. However, it is
noted that the cellular transfer efﬁciency with existing
inorganic nanoparticles is relatively low. Being chemically sta-
ble, inorganic nanoparticles remain unchanged during the
whole delivery process and they should not be biodegraded
in plasma and cytoplasm of a human body (Xu et al., 2006).
Speciﬁcally, GNPs emerged as an attractive candidate for
delivery of various biomolecules into their targets (Jin et al.,
2014; Duncan et al., 2010; Pissuwan et al., 2011). GNPs can
also be used as adjuvant for enhancing the efﬁcacy of radiation
therapy and as contrast agents for various modalities involved
in therapeutic and diagnostic applications (Dorsey et al.,
2013). GNPs have unique chemical and physical properties
and can effectively transport and unload the pharmaceuticals
in cellular systems. Moreover, photophysical properties of
gold could trigger drug release at remote places (Skirtach
et al., 2006; Connor et al., 2005). GNPs in particular are an
excellent intracellular targeting vector because it can be
engineered into desirable size, surface to achieve good biocom-
patibility with functionalities. GNPs have a widespread
distribution in the human body, although internalization of
GNPs depends upon the types of the cell (Coulter et al.,
2012). The presence of GNPs could create an oxidative envi-
ronment; it also affects the regulation of cellular stress
response mechanisms and at the same time induces the forma-
tion of autophagosomes, possibly to protect the cell from suc-
cumbing to oxidative stress. Surface modiﬁcation of GNPs
also enhances the stability of biomolecules by improving zeta
potential and reduces the side effects by preventing nonspeciﬁc
interactions (He et al., 2003). It is interesting to mention that
most modiﬁers provide a very good protection for biomole-
cules from being degraded by enzymes in plasma, which is lar-
gely due to the steric effect and electrostatic repulsion from the
modiﬁers. Secnidazole (a,2-Dimethyl-5-nitro-1H-imidazole-
1-ethanol) is structurally related to the commonly used
5-nitroimidazole metronidazole and tinidazole. The physico-
chemical, molecular and other related properties of the bulk
drug have been established well (Wells, 1987). Nanoparticle
mediated delivery systems have several distinguished advanta-
ges. In a normal drug administration, drug molecules affect the
target cell as well as the nonspeciﬁc cells via blood circulation
with no preference for drug molecules to recognize targeted
cells. Whereas, in nanoparticle mediated drug delivery system
surface ﬁctionalization of the nanoparticles determines the
driving forces for transfection (Zhu et al., 2004;
Pinto-Alphandary et al., 2000; Tom et al., 2004). Also, grafting
speciﬁc biomolecules on nanoparticles provides site speciﬁc
delivery of nanoparticles into cells. Human Serum Albumin(HSA) is acidic in nature, soluble in a wide range of pH, has
been used as a capping agent and linker between drug and
nanoparticles. HSA, readily available, biodegradable, lacks
toxicity and immunogenicity, makes the system more stable
and efﬁcient by protecting drugs by limiting nonspeciﬁc inter-
actions markedly, which makes it an ideal system for drug
delivery (Sripriyalakshmi et al., 2014). There are many reports,
where nanocarriers have been proved to be a very effective
cargo of the drugs like gentamycin (Lecaroz et al., 2006), ampi-
cillin (Fattal et al., 1989), amphotericin B (Umamaheshwari
et al., 2004), anticancer antibodies and drugs (Marega et al.,
2012; Moghimi, 2006). Nanoconjugates also help in reducing
the dose of certain drugs, as there are many drugs which are
required in very high concentration in human body and hence
produce toxic effect (Schellie and Groshong, 1999). The accu-
rate effect of conjugated drug could be determined only if
quantiﬁcation of conjugated drug is exactly known. Hence,
in the present study, an attempt was made to develop a two
step method to biosynthesize HSA encapsulated gold
nanoparticles and eventually, their bioconjugation with
secnidazole. The secnidazole-conjugated gold nanoparticles
(Au-HSA-Snd) were used against Klebsiella pneumonia (NCIM
No. 2957) and Bacillus cereus (NCIM No. 2156). This system
was found to be highly effective against these microbes in com-
parison to pure secnidazole.
2. Materials and methods
In this study in vitro synthesis of gold nanoparticles was done
by taking a total reaction mixture of 3 ml containing 1.0 mM,
each of freshly prepared H[AuCl4] and Na2SO3, 100 lg of
Human Serum Albumin (HAS), 1.0 mM a-NADPH (a-Nico-
tinamide adenine dinucleotide phosphate, reduced disodium
salt) and 1.66 U (100 lg protein) of sulﬁte reductase (Kumar
et al., 2007). The reaction mixture was incubated, under anaer-
obic conditions at 25 C. Reactions performed in the absence
of a-NADPH enzyme, HSA and with the inactivated enzyme
were used as a control. Samples were removed at regular
intervals and analyzed in UV–VIS spectroscopy to conﬁrm
for the nanoparticle formation. On completion of the
reaction, gold nanoparticles were collected by centrifugation
(30,000g, 30 min), washed twice with Milli Q water and the
unbound proteins were removed by treating with 50% v/v of
1,4-Dioxane and used for further characterization.
For characterization, UV–VIS spectrophotometry mea-
surements were performed on a Shimadzu dual-beam spectro-
photometer (model UV-1601 PC) operated at a resolution of
1 nm in the quartz cuvette.
Transmission Electron Microscopy (TEM) was done by
drying a drop of gold nanoparticle solution on carbon coated
TEM copper grids followed by measurements on (TEM) FEI
Company, Tecnai G2 Spirit BioTWIN operated at an accel-
erating voltage of 80 kV.
Scanning Electron Microscopy was done by drying a drop
of as-synthesized GNP solution on glass slides and then coated
44 S. Khan et al.with gold. The morphology of nanoparticles was examined
under a scanning electron microscope (JEOL JSM 5200).
The mean particle size of HSA encapsulated biosynthesized
gold nanoparticles (Au-HSA) and secnidazole bioconjugated
nanoparticles (Au-HSA-Snd) was measured with a Dynamic
Light Scattering (DLS) particle size analyzer (Zetasizer
Nano-ZS, Model ZEN3600, Malvern Instrument Ltd, Mal-
vern, UK). The powder of the sample was diluted to a concen-
tration of 0.5% (Wt/v) in deionized water and sonicated for
1 min before measurement. The sample was taken in a
DTS0112-low volume disposable sizing cuvette of 1.5 ml.
Mean particle size was the average of triplicate measurements
for a single sample. Zeta potential was also measured using a
Zetasizer Nano-ZS, Model ZEN3600 (Malvern Instrument
Ltd, Malvern, UK).
In vitro synthesized Au-HSA nanoparticles were bioconju-
gated to secnidazole with the free carboxylate group present
on HSA by using the activator 1-Ethyl-3-(3-dimethylamino-
propyl)-carbodiimide (EDC) (Timkovich, 1977; Hermanson,
1996). The coupling was performed in a reaction mixture of
5 ml containing 50 mM MES/HEPES buffer, 250 lg of Secni-
dazole and 250 lg of Au-HSA nanoparticles whereas 5 mM
EDC was added in aliquots within 3 hours at 30 C in the reac-
tion mixture.
Bioconjugates were separated from unconjugated Au-HSA
nanoparticles by passing the reaction mixture through Biogel
P-30 gel ﬁltration column pre-equilibrated with 20 mMHEPES
buffer (pH 6.0) containing 150 mM NaCl. The fractions were
scanned between 200 and 900 nm and subsequently, those frac-
tions were pooled which showed absorbance at 320 nm/525 nm
due to the presence of secnidazole conjugated with Au-HSA
nanoparticles. The pooled samples were dialyzed against dis-
tilled water and used for further characterization.
Further, Loading efﬁciency (LE) of secnidazole drug on
Au-HSA nanoparticles was determined by a high performance
liquid chromatography (A Shimadzu-model HPLC equipped
LC-20 AT pump, SPD-20 A UV/VIS detector, Rheodyne
injector ﬁtted with a 20-ll loop was used and the data were
recorded and evaluated using Spinchrom software) at 25 C
with a reversed-phase C-18 column, Luna Column (5 lm,
250 · 4.6 mm inner diameter) using a mobile phase consisting
of buffer: 0.01 M KH2PO4: ACN (85:15) at a ﬂow rate of
1 ml/min with UV detection at 228 nm. The mobile phase
was ﬁltered through 0.22-lm nylon ﬁlter prior to use. The
experiments were performed in triplicate. Quantitative deter-
mination of secnidazole was performed according to the
method described by Rivera et al. (2000). The pure drug cali-
bration curve was plotted in the linear range of 2-25 lg/ml.
The percentage loading of secnidazole to GNPs was calculated
by using RP-HPLC C-18 column. The standard curve of the
pure secnidazole drug was established and unbound drug
was calculated from the standard curve. Amount of bioconju-
gated drug was calculated by subtracting unbound drug from
the total amount of drug added. The exact amount of biocon-
jugated drug was calculated using the following equation:
% Bioconjugation ¼ ðAmount of drug Bioconjugated
=Total drug addedÞ  100
Efﬁcacy of bioconjugated secnidazole was estimated by
evaluating Minimum Inhibitory Concentration (MIC) of
Au-HSA-Snd and pure secnidazole drug against K. pneumonia(NCIM No. 2957) and B. cereus (NCIM No. 2156) in Luria–
Bertani (LB) broth using the protocol described by
Amsterdam, 1991. Bacteria grown to mid-logarithmic phase
were harvested by centrifugation, washed with 10 mM sodium
phosphate buffer (SPB) at pH 7.4, and diluted to 2 · 105 col-
ony forming units (CFU)/ml in SPB containing 0.03%
Luria–Bertani (LB) broth. Au-HSA-Snd were serially diluted
in 50 lL of LB medium in 96-well microtitre plates to achieve
the desired concentrations with bacterial inoculum
(5 · 104 CFU per well). After incubation at 37 C overnight,
the MIC was taken as the lowest Au-HSA-Snd concentration
at which growth was inhibited. For the agar plate count
method (Stenger et al., 1998), a 25 lL aliquot of bacteria at
1 · 105 CFU/ml in SPB containing 0.03% LB broth was incu-
bated with 25 lL of diluted compounds for 2 h at 37 C
(Hamamoto et al., 2002). The mixtures were serially diluted
10-fold in SPB, plated on LB agar and incubated overnight
at 37 C. Bacterial colonies were enumerated the following
day. Autoclaved water and only non conjugated gold nanopar-
ticles (Au-HAS) were used as a negative control in the experi-
ment. After having determined the MIC of bacteria from the
wells of the microtitre plate with no visible bacterial growth,
samples were removed for serial subcultivation of 2 lL into
microtitre plates containing 100 lL of broth per well and fur-
ther incubated for 24 h to determine the Bactericidal Activity
Measurement (MBC). The lowest concentration with no visi-
ble growth was deﬁned as MBC, indicating 99.5% killing of
the original inoculums. The optical density of each well was
measured at a wavelength of 620 nm by microtitre plate man-
ager 4.0 (Bio-Rad laboratories) and compared with a control.
Autoclaved water and only non conjugated gold nanoparticles
(Au-HSA) were used as a negative control in the experiment.
Two replicates were done for each compound and the experi-
ment was repeated twice.
3. Results and discussion
The targeted delivery of drugs is one of the most promising
and actively developing areas in the medicinal use of GNPs
(Duncan et al., 2010). Antibiotics and antitumor agents are
the most popular objects of target delivery. The conjugation
of GNPs with a good number of drugs such as 6-mercaptopur-
ine (Podsiadlo et al., 2008), 5-ﬂuorouracil (Agasti et al., 2009),
platinum complexes (Dhar et al., 2009), kahalalide (Hosta
et al., 2009), doxorubicin (Asadishad et al., 2010), and many
more has been done with great success. On the contrary,
successful conjugations of antibiotics such as ampicillin, strep-
tomycin, kanamycin, hentamycin, neomycin, ciproﬂoxacin,
gatiﬂoxacin, and norﬂoxacin were (Saha et al., 2007; Grace
and Pandian, 2007) not done with gold nanoparticles. Never-
theless, they were found 12–40% more active when mixed with
colloidal gold than that of the antibiotic used alone, depending
on the antibiotic. Hence, it was proved that the antibacterial
activity of antibiotics was enhanced by GNPs but stable con-
jugates of nanoparticles coated with antibiotic molecules are
required to enhance the antibacterial activity exceptionally
high. It has also been proved that upon intravenous injection,
GNP conjugated with drugs rapidly accumulates in defected
cells and is not detected in cells of the liver, spleen, and other
healthy organs (Mukherjee et al., 2005). GNPs have antiangio-
genic properties (Mukherjee et al., 2005) and enhance the
Figure 1 Schematic representation of biosynthesis of Human Serum Albumin capped Gold nanoparticles (Au-HSA) by using Nitrate
Reductase as reducing agent and eventually their bioconjugation with secnidazole drug (Au-HSA-Snd).
Figure 2 Characterization of HSA encapsulated bioengineered Pure GNP (GNP-HSA) under (A) UV–VIS spectroscopy (B) Scanning
Electron Microscopy (B) Transmission Electron Microscopy (C) Zeta Potential and (D) Dynamic Light Scattering.
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(Mukherjee et al., 2007) and suppress the proliferation of mul-
tiple myeloma cells (Bhattacharya et al., 2007).
There has been much less data on other drugs conjugated
with gold nanoparticles (Dykman and Khlebtsov, 2011). In
the present study, secnidazole was successfully bioconjugatedwith gold nanoparticles (Au-HSA) with accuracy and the
effectiveness of gold nanoparticle bioconjugated secnidazole
(Au-HSA-Snd) was tested against K. pneumonia (NCIM No.
2957) and B. cereus (NCIM No. 2156) in comparison to its
unconjugated form. This system was used as a vehicle to deli-
ver secnidazole effectively at the targeted cells. Fig. 1 illustrates
Figure 3 Characterization and conﬁrmation of bioconjugation of secnidazole with Pure GNP (GNP-HSA) in order to synthesize
secnidazole bioconjugated GNP (GNP-HSA-Snd) under (A) Transmission Electron Microscope (B) Dynamic Light Scattering and (C)
Zeta Potential.
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encapsulated gold nanoparticles (Au-HSA) by nitrate
reductase and eventually their bioconjugation with secnidazole
drug. The formation of the Au-HSA has been conﬁrmed by
their representative surface plasmon resonance (SPR) band
measured as measured by optical density in UV–VIS absorp-
tion spectroscopy. The SPR absorption spectra of Au-HSA
and secnidazole-conjugated Human Serum Albumin coated
gold nanoparticles (Au-HSA-Snd) are plotted in Fig. 2A.
The size and concentration of GNPs between 5 and 100 nm
can be determined by using the Classical Guass method
(Wolfgang et al., 2007). The linear regression equation
(kmax = 515.04 + 0.3647d) explains the relation between par-
ticle diameter and kmax (He et al., 2005). Hence, the absor-
bance band shifts toward red with the increase in diameter
of the particles and intensity of peak decreases with a decrease
in particle size due to the reduced mean free path of the elec-
trons due to collisions of electrons with the particle surface
(Haiss et al., 2007).The topographical studies such as surface structure and
morphology of Au-HSA, were performed under SEM and size
of nanoparticles was determined manually using Gatan digital
micrograph which showed spherical shaped nanoparticles with
an average size of 7 ± 2 nm (Fig. 2B). High resolution images
were acquired using TEM (Fig. 2C). The stability of the
Au-HSA was conﬁrmed by zeta potential which was found
to be 13.3 mV (Fig 2D), which can be one of the reasons
for their long term stability and the electrostatic repulsive
forces between the nanoparticles might protect them from get-
ting closer and thereby preventing agglomeration or clumping
in aqueous suspension. Dynamic Light Scattering (DLS) also
reveals that the particles are smaller in size and uniformly dis-
tributed (Fig 3E). The hydrodynamic diameter of nanoparti-
cles appears large (18 ± 3 nm) in DLS due to the interaction
and binding of solvent to the surface of nanoparticles. The bio-
conjugation of secnidazole with Au-HSA was conﬁrmed by the
SPR absorption band for Au-HSA-Snd which appeared at
525 nm, with a signiﬁcant broadening and a slight decrease
Figure 4 RP-HPLC chromatograms for (A) pure secnidazole drug and (B) bioconjugated drug (Au-HSA-Snd).
Figure 5 (A) Antibacterial test of secnidazole bioconjugated gold nanoparticles (GNP-HSA-Snd) in comparison to pure secnidazole
drug against (A) Bacillus cereus (B) Klebsiella pneumoniae.
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527 nm (Fig 2A) because the plasmon resonance is a surface
phenomenon which alters after attachment of any ligand at
the surface. The ligand binding signiﬁcantly affects the absorp-
tion intensity and full width at half maximum (FWHM) of
absorption band. The observed broadening in absorption band
is attributed to the attachment of secnidazole drug at the
surface of nanoparticles. The absorption spectrum ofAu-HSA-Snd reveals two peaks at 320 nm and 525 nm are
corresponding to secnidazole aromatic nitrite transitions
and GNPs respectively, suggesting its binding to GNPs.
Further, TEM micrographs of secnidazole-conjugated gold
nanoparticles (Au-HSA-Snd) also reveal the attachment of
secnidazole (and consequent enlargement of the particles) as
a biomolecular layer at the surface, resulting in some blurring
of the micrograph (3A). Also, secnidazole-conjugated gold
48 S. Khan et al.nanoparticles (Au-HSA-Snd) appear bigger than non conju-
gated (Au-HSA) one due to subsequent enlargement of nano-
particles (Fig 3B). The zeta potential of Au-HSA-Snd was
found to be7.97 mVwhich is well in the range required for sta-
ble emulsion (Fig 3C). The decrease in zeta potential may be
attributed to the decrease of the free amino groups on the Au-
HSA-Snd after bioconjugation of the secnidazole drug to these
groups. The quantitative estimation of bioconjugated secnidaz-
ole with Au-HSA was determined by RP-HPLC chromatogra-
phy by using the C-18 column. The amount of bioconjugated
secnidazole was found to be 70% indicating efﬁcient binding
of secnidazole with Au-HSA-Snd nanoparticles (Fig 4). The
retention time for pure secnidazole drug and Au-HSA-Snd is
13.147 min (Fig 4A) and 13.2 min (Fig 4B), respectively. The
slight change in retention time is due to variation of pH in the
mobile phase to themedium of drug. The retention time for gold
nanoparticle bound secnidazole is 2.6 min (Fig 4B). Au-HSA-
Snd Au-HSA-Snd nanoparticles and pure secnidazole drug
(Fig 5) were evaluated for antibacterial activity against repre-
sentative bacteriaK. pneumonia (NCIMNo. 2957) andB. cereus
(NCIM No. 2156). Autoclaved water and only Au-HSA were
used as negative control. The MIC of Au-HSA-Snd nanoparti-
cles against K. pneumonia (NCIM No. 2957) and B. cereus
(NCIM No. 2156) were found to be 0.35 lg/ml and 0.43 lg/
ml, respectively, whereas MIC of the pure secnidazole drug
against K. pneumonia (NCIM No. 2957) and B. cereus (NCIM
No. 2156) were found to be 4.3 and 6.07 lg/ml, respectively.
The efﬁciency of bioconjugated secnidazole got improved by
12.2 and 14.11 times, respectively, in comparison to pure
secnidazole. The pure gold nanoparticles were not found to be
toxic against any bacterial strain. In conclusion, Secnidazole-
bioconjugated Human Serum Albumin coated gold nanoparti-
cles (Au-HSA-Snd) were developed as a suitable vehicle for tar-
geting drug delivery system to enhance therapeutic effects of
secnidazole drug and reduce its side effects. Although there
are certain limitations of this system that all drugs cannot be
bioconjugated with gold nanoparticles and their toxicity level
changes with change in drug. In future a detailed mechanism
of action including internalization in the targeted cells of Au-
HSA-Snd has to be elucidated tomake drug evenmore effective.
4. Conclusions
Secnidazole-bioconjugated Human Serum Albumin coated
gold nanoparticles (Au-HSA-Snd) were developed as an ideal
targeted drug delivery system to enhance therapeutic effects
signiﬁcantly of secnidazole drug and reduce its side effects.
This system not only makes the drug stable, but also reduces
the dose with enhanced potency.
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